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Abstract
Endostatin, the C-terminal domain of collagen XVIII, binds to transglutaminase-2 (TG-2) in a
cation-dependent manner. Recombinant human endostatin binds to TG-2 with an affinity in the
nanomolar range (KD = 6.8 nM). Enzymatic assays indicated that, in contrast to other extracellular
matrix proteins, endostatin is not a glutaminyl substrate of TG-2 and is not cross-linked to itself by
the enzyme. Two arginine residues of endostatin, R27 and R139, are crucial for its binding to
TG-2. They are also involved in the binding to heparin (Sasaki et al., EMBO J 18:6240–6248),
and to α5β1 and αvβ3 integrins (Faye et al., J Biol Chem 284:22029–22040), suggesting that
endostatin is not able to interact simultaneously with TG-2 and heparan sulfate, or with TG-2 and
integrins. Inhibition experiments support the GTP binding site of TG-2 as a potential binding site
for endostatin. Endostatin and TG-2 are colocalized in the extracellular matrix secreted by
endothelial cells under hypoxia, that stimulates angiogenesis. This interaction occurring in a
cellular context might participate in the concerted regulation of angiogenesis, and tumorigenesis
by the two proteins.
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INTRODUCTION
Endostatin (ES) is a C-terminal fragment of the α1 chain of collagen XVIII, which inhibits
angiogenesis, and tumor growth [1,2]. It binds to α5β1 and αvβ3 integrins [3,4] glypicans 1
and 4 [5], and to vascular endothelial growth factor receptor-2 (VEGFR-2, Flk1/KDR) [6]
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on the surface of endothelial cells. The binding of human endostatin to α5β1 integrin leads
to the inhibition of focal adhesion kinase/c-Raf/MEK1/2/p38/ERK1 mitogen-activated
protein kinase pathway [7]. Endostatin also inhibited the binding of VEGF165 to both
endothelial cells and to the purified extracellular domain of KDR/Flk-1. Furthermore,
endostatin blocks VEGF-induced tyrosine phosphorylation of KDR/Flk-1 and activation of
ERK, p38 MAPK, and p125(FAK) in human umbilical vein endothelial cells [6].
Endothelial cells are a rich source of transglutaminase-2 (TG-2) [8], and this enzyme plays
an important role at the surface of those cells. For example, evidence has been reported for
its externalization and its co-localization with the β1 integrin [9]. Cell surface TG-2 interacts
with integrins of the β1 and β3 subfamilies in focal adhesion sites [10], and the formation of
a complex between TG-2 and VEGFR-2 has been proposed as a mechanism for modulation
of endothelial cell response to VEGF [11]. Conflicting in vivo studies have proposed that the
enzyme both stimulates and inhibits angiogenesis [12,13]. However application of
exogenous TG-2 blocks angiogenesis in a dose-dependent manner in an in vitro
angiogenesis assay without causing cell death, by a mechanism that involves increased
accumulation of extracellular matrix proteins [14]. This Ca2+-dependent enzyme catalyzes
post-translational modification of proteins by the formation of γ-glutamyl-ε-lysine bonds
between glutamine and lysine residues [15,16,17]. TG-2 is a multifunctional enzyme which
undergoes a GTP-binding/GTPase cycle, with guanine nucleotide and calcium binding
reciprocally regulating its transamidation activity [18].
Endostatin and TG-2 share several extracellular partners such as nidogen, SPARC, collagen
VI, and the β-amyloid peptide [15,19,20,21,22]. Both proteins are also able to bind to
heparin [19,23,24], α5β1 and αvβ3 integrins [3,4,10], and VEGF receptor-2 [6,11]. They are
involved in angiogenesis, and are increased in brain after trauma [25,26]. Furthermore they
may play a role in Alzheimer’s disease. Endostatin is released by neurons and accumulates
in amyloid plaques [27] and TG-2 co-localizes with the pathological lesions in Alzheimer's
disease brain [28,29]. All these common properties prompted us to investigate the possible
existence of an interaction between these two proteins, and we have recently shown that
endostatin interacts with TG-2 [22]. We report here that endostatin binds to TG-2 with an
affinity in the nanomolar range in a calcium-dependent manner. Endostatin is not a
glutaminyl substrate of TG-2 in vitro, and it is not cross-linked to itself by the enzyme.
Since endostatin and transglutaminase-2 are both involved in the regulation of angiogenesis,
and have been implicated in Alzheimer’s disease, it is likely that their interaction is of major
importance for the modulation of endothelial cell migration and/or proliferation, and for the
formation and/or the stabilization of amyloid plaques in neurodegenerative diseases.
EXPERIMENTAL
Proteins and antibodies
Recombinant human TG-2 was purchased from two different suppliers (Immundiagnostik,
Germany, and Covalab, France). Guinea pig TG-2 extracted from liver was from Sigma-
Aldrich (St Quentin Fallavier, France). Recombinant endostatin, the C-terminal domain of
collagen XVIII (NC1), and NC1 mutants (D104N and R27A/R139A) were produced in
human embryonic kidney cells expressing Epstein-Barr virus nuclear antigen (HEK 293-
EBNA cells, [4,22,23]. Transfected HEK 293 cells expressing wild type or mutant
endostatin and the NC1(XVIII) domain were a generous gift of Naomi Fukai and Reidunn
Jetne (Harvard Medical School, Boston, USA). To avoid the confusion due to two different
numberings reported for endostatin in the literature, amino acids residues are numbered
starting from the first amino acid residue of endostatin (i.e. His1, corresponds to His132
when numbering starts from the first amino acid of the entire C-terminal domain NC1 of
collagen XVIII). Both proteins were tagged by the peptide Flag at the N- or the C-terminus
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for endostatin and at the C-terminus for the NC1 domain. The conditioned culture media
were filtered through 0.22-µm filters and applied to a 5-ml heparin HiTrap (GE Healthcare,
Uppsala, Sweden) for wild-type and mutant endostatin, and to an anti-Flag M2 affinity
column (Sigma-Aldrich) for wild-type and mutant NC1. Endostatin was further purified by
gel filtration on a Superdex S75 column (60 cm×2.6 cm, GE Healthcare), and the NC1
domain was further purified on a Sephacryl S200 column (60 cm×2.6 cm, GE Healthcare).
The purity of proteins was assessed by SDS-PAGE and immunoblotting. The purified
proteins were concentrated by ultrafiltration and stored at −80°C. Recombinant human
endostatin expressed in Pichia pastoris was from Calbiochem (San Diego, CA). Anti-TG-2
monoclonal antibody (CUB7402) was from NeoMarker (Fremont, CA, USA). Bovine
collagen XI was a generous gift from Dr. Marie-Claire Ronzière (UMR 5086, CNRS,
University Lyon 1, France).
Preparation of a polyclonal antibody against human endostatin
Recombinant human endostatin with a Flag peptide at the C-terminus was used for the
immunization of New Zealand white rabbits. Endostatin diluted in phosphate buffered saline
(PBS, 660 µg/ml) emulsified with an equal volume of Freund's complete adjuvant was
injected intra-dermally. Two booster injections with Freund's incomplete adjuvant were
performed 14 and 28 days after the first injection. The IgG fraction was purified from the
immunserum by affinity chromatography on Protein A Ceramic Hyper D®F (Pall Life
Sciences, Saint-Germain en Laye, France). IgGs were eluted by 0.1 M citric acid pH 3, and
neutralized with 1 M potassium phosphate buffer pH 9. The polyclonal antibody was
assayed by immunoblotting, and solid-phase assays. The antibody reacted with wild type
and mutant endostatin, and with the wild type and mutant NC1(XVIII) domains
(Supplementary material, Fig S1).
Solid-phase binding assays
Transglutaminase was diluted in 25 mM Tris·HCl, 150 mM NaCl, pH 7.4 (TBS) for coating.
Endostatin and the NC1(XVIII) domain were diluted in 10 mM PBS pH 7.4 containing 138
mM NaCl, 27 mM KCl, or in 25 mM Tris·HCl, 150 mM NaCl, pH 7.4 (TBS). Aliquots (100
µl) were added to the wells of a 96-well microplate (MaxiSorp, Nunc, Thermo Fisher
Scientific, Roskilde, Denmark). Plates were incubated overnight at 4°C, and wells were
blocked for 2 h with 5% (w/v) BSA in TBS. The plates were incubated for 2 h at room
temperature with TG-2 diluted in TBS containing 1 mM EDTA with or without cations (8
mM CaCl2, MgCl2, or MnCl2). The wells were washed three times with TBS containing
0.1% (v/v) Tween 20. Bound transglutaminase was detected by a monoclonal anti-TG-2
antibody diluted 1:1000 in TBS + 0.1% (v/v) Tween 20 for 1 h at room temperature. Bound
endostatin was detected with the polyclonal anti-endostatin antibody diluted 1:1000. The
wells were washed 3 times with TBS, 0.1% (v/v) Tween 20, and were then incubated with
either alkaline phosphatase-conjugated or peroxidase-conjugated secondary antibodies. The
immunological reaction was detected by adding p-nitrophenyl phosphate (absorbance
measured at 405 nm), or 3,3',5,5'-tetramethylbenzidine (absorbance was measured at 450
nm). Nonspecific binding was measured in BSA-coated wells, and was subtracted from the
values measured in endostatin-, or transglutaminase-coated wells. For inhibition experiments
by GTP, endostatin was diluted in 25 mM Tris·HCl, 150 M NaCl pH 7.4 (0.1 µg/well), and
incubated overnight at 4°C in a 96-well microplate (MaxiSorp, Nunc). Wells were blocked
for 2 h with 5% (w/v) BSA in TBS. TG-2 was preincubated in TBS containing 8 mM CaCl2
with several concentrations of GTP (0–100 µM) for 1 h at room temperature, before
incubation for 2 h at room temperature. The binding of TG-2 to endostatin was performed as
described above. All assays were performed in triplicate.
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Surface plasmon resonance arrays
SPR arrays were performed using a Biacore Flexchip system (GE Healthcare, Sweden) as
described previously [22]. This available high-density array platform is able to follow the
binding of a single analyte to 400 target spots at a time. Proteins (50 and 200 µg/ml) were
spotted in triplicate at two concentrations onto the surface of a Gold Affinity chip (GE
Healthcare) using a non-contact PiezoArray spotter (Perkin Elmer, Courtaboeuf, France).
Six drops of 330 pl each were delivered to the surface of the chip (spot diameter: 250–300
µm, spotted amount: 100–400 pg/spot). The chips were then dried at room temperature and
stored under vacuum at 4°C until their insertion into the Biacore Flexchip instrument. The
chip was blocked with Superblock buffer (Pierce, Thermo Scientific, Brebières, France) for
5×5 min. The blocked chip was then equilibrated with PBS, 0.05% (v/v) Tween 20 at 500
µl/min for 90 min. TG-2 (500 nM) was flowed at 25°C over the chip surface for 25 min at
the same flow rate. The dissociation of the endostatin-TG-2 complex was monitored in
buffer flow - PBS, 0.05% (v/v) Tween 20 - for 40 min. Data collected from reference spots
(gold surface), and from buffer spots were subtracted from those collected on spotted
proteins to obtain specific binding curves.
Surface plasmon resonance binding assays
The SPR binding assays were performed in a Biacore T100 instruments (GE Healthcare).
Recombinant human endostatin (50 µg/ml in 10 mM maleate buffer, pH 6.2) was covalently
immobilized to the dextran matrix of a CM5 sensor chip via its primary amine groups
according to the manufacturer's instruction (amine coupling kit, GE Healthcare) at a flow
rate of 5 µl/min with 10 mM Hepes buffer pH 7.4 containing 0.15 M NaCl and 0.05% (v/v)
P20 (HBS-P+ buffer, GE Healthcare) as running buffer. An immobilization level ranging
between 1800 and 2000 resonance units (RU) was obtained; a control flow cell was prepared
with 10 mM maleate buffer pH 6.2. ZnCl2(1 mM) was added to the running buffer for
binding experiments. Sensorgrams collected on the control flow cell were automatically
subtracted from the sensorgrams obtained on immobilized endostatin to yield specific
binding responses. Binding assays were performed at 25 °C, but the sample compartment of
the Biacore T100 was kept at 4°C to maintain transglutaminase-2 in its native state. Kinetic
and affinity constants were calculated by injecting several concentrations of
transglutaminase-2 (8–130 nM) in the presence of 2 mM CaCl2, over immobilized
endostatin at 60 µl/min. The complexes were dissociated by a pulse (60 s) of 1.5 M NaCl +
2 M guanidinium chloride. The kinetic rates, ka and kd(association and dissociation rate
constants, respectively), were calculated using the Biacore T100 evaluation software 2.0.1.
Apparent equilibrium dissociation constants (KD) were calculated as the ratio of kd/ka for a
1:1 (Langmuir) interaction model. Inhibition experiments were carried out by preincubating
TG-2 (130 nM) with 1 mM GTP for 15 min at room temperature before injecting the
mixture over endostatin immobilized on the sensor chip.
Cross-linking experiments
Guinea pig TG-2 (5 mU/ml, Sigma-Aldrich) was incubated with recombinant human
endostatin expressed in mammalian cells (10 µg/ml), the biotinylated peptide TVQQEL
used as an acyl donor (30) (Assay mix A5731, Sigma-Aldrich) and 1 mM dithiothreitol. The
reaction was carried out for 2, 5, 10, 20, 30 and 60 min at room temperature and was
stopped by addition of 20 mM EDTA. Control experiments were performed with TG-2 and
endostatin alone. The reaction products were analyzed by SDS-PAGE and by
immunoblotting with either streptavidin-peroxidase, or with the polyclonal anti-endostatin
antibody, followed by chemiluminescence detection (ECL, GE Healthcare). In another series
of experiments, TG-2 (10 mU/ml) was incubated with endostatin (10 µg/ml), biotin-X-
cadaverin (2 mM, Sigma-Aldrich), 8 mM CaCl2 and 1 mM dithiothreitol. The reaction was
carried out for 120 min at room temperature, and was stopped by addition of 20 mM EDTA.
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Control experiments were performed with either TG-2 or endostatin alone. The reaction
products were analyzed as described above.
Cross-linking experiments: Reaction between endostatin (476 nM) and biotinylated peptide
TVQQEL-OH mediated by guinea pig TG-2 (5 mU/ml). Reactions were carried out for 60
min at room temperature with or without GTP (µM). Results were analyzed by
immunoblotting using A) extravidin-peroxidase, and B) polyclonal antibody against
endostatin.
Immunocytochemistry
Primary cultures of human umbilical vein endothelial cells (HUVEC) were grown in
endothelial cell growth medium 2 (PromoCell, Heidelberg, Germany). The cells were used
for immunofluorescence experiments between passages 2 and 5. HUVEC were seeded on
glass coverslips and cultivated in complete medium in normoxia or hypoxia (1% O2). The
cells were then fixed with cold methanol for 5 minutes before blocking with 10% (v/v)
normal goat serum in PBS. They were then incubated either with the anti-endostatin
antibody, or with the antibody directed against TG-2 diluted in PBS containing 1% (v/v)
normal goat serum. Secondary goat antibodies directed against rabbit or mouse IgG coupled
to AlexaFluor-488 or -555 were from Invitrogen (Cergy Pontoise, France). Nuclei were
stained with TO-PRO-3 (Invitrogen). Coverslips were mounted with Mowiol and observed
with a TCS SP2 confocal microscope (Leica Microsystems, Nanterre, France).
RESULTS
Transglutaminase binds to monomeric endostatin and to the C-terminal domain of
collagen XVIII
The binding of human TG-2 to endostatin and to the trimeric NC1 domain of collagen XVIII
was demonstrated by SPR arrays (Figure 1A). Under the same experimental conditions,
TG-2 was found previously to bind to known ligands, heparin and heparan sulfate [31),
collagen XI [32] (Supplementary material, Fig. S2), α5β1 and αvβ3 integrins [10], and
amyloid Aβ peptide [26]. The interaction was confirmed by solid-phase assays (Figure 1B),
and was also observed with guinea pig TG-2 (Figure 2B). Several sources of TG-2 and
endostatin were used to support the existence of the interaction between these two
molecules.
The binding properties of the D104N mutant were investigated because individuals with the
homozygous D104N polymorphism in the COL18A1 gene have a high risk of occurrence of
cancer [33,34]. The D104N mutation did not alter the folding of endostatin and of the
NC1(XVIII) domain as assessed by intrinsic fluorescence (Supplementary material Fig. S3).
This mutation did not affect significantly the ability of endostatin, or of the NC1 domain of
collagen XVIII, to bind to transglutaminase-2 (Figure 1B, and Figure 3B). In contrast, the
double R27A/R139A NC1 mutant that has lost its capacity to bind heparin [19] but is
properly folded as assessed by fluorescence spectroscopy (Supplementary material Fig. S3),
bound to TG-2 to a lesser extent (31% compared to the wild type NC1 domain) (Figure 1B).
The binding of recombinant endostatin (i.e. expressed in yeast or in mammalian cells) to
immobilized TG-2 was concentration-dependent (Figure 2A). Similar results were obtained
in the reverse orientation when TG-2 was incubated with endostatin-coated wells (Figure
2B).
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The binding of endostatin to transglutaminase-2 is dependent upon cations
Binding assays were performed with human recombinant TG-2 in the presence of 1 mM
EDTA to remove residual cations from the sample and to analyze the effects of different
cations added at 8 mM. In absence of any cation, TG-2 did not bind significantly to
endostatin (Figure 3A). The addition of cations increased the binding by ~ 2-fold for MgCl2,
~ 10-fold for MnCl2, and ~ 38-fold for CaCl2 (Figure 3A). Similar increase in binding was
obtained with guinea pig TG-2 in the presence of cations (Supplementary material Fig. S4).
Calcium was used for further experiments because it was the most efficient in promoting
endostatin binding. In presence of 8 mM CaCl2, the binding of TG-2 to wild-type endostatin
and to the D104 N endostatin mutant was saturable (Figure 3B).
Endostatin binds to transglutaminase with high affinity
Kinetic analysis was performed by injecting guinea pig TG-2 at several concentrations over
immobilized endostatin produced either in mammalian cells (Supplementary material Fig.
S5A) or in yeast (Supplementary material Fig. S5B). The sensorgrams were fitted to a 1:1
Langmuir model using the Biacore T100 evaluation software (2.0.1), and kinetics and
affinity constants were calculated (Table 1). The affinity constants were 6.8 nM, and 5.6 nM
for recombinant endostatin produced from mammalian cells and yeast, respectively (Table
1).
TG-2 is regulated by calcium and GTP. The transamidating activity of the enzyme is
inhibited by GTP in an allosteric fashion, whereas CaCl2 partially reverses GTP inhibition
[35]. We performed inhibition experiments with GTP, a reversible inhibitor of the cross-
linking activity of TG-2, to determine if it was able to interfere with the binding of TG-2 to
endostatin. Recombinant TG-2 in TBS containing 8 mM CaCl2 was preincubated with
increased concentrations of GTP (0–100 µM) for 1 h at room temperature. It was then added
to a 96-well microplate coated with recombinant human endostatin expressed in mammalian
cells and incubated for 2 h at room temperature. We observed a decrease in the binding level
of TG-2 to endostatin upon the addition of increasing concentrations of GTP (Figure 4A).
This inhibition was confirmed by SPR experiments where the binding of guinea pig TG-2 to
recombinant human endostatin expressed in mammalian cells was nearly abolished (96.7%
inhibition) by 1 mM GTP (Figure 4B). A similar effect was observed with human endostatin
produced in yeast (100% inhibition, data not shown). The above results suggest that either
endostatin binds to TG-2 at the same site as GTP, or that the interaction with endostatin
requires TG-2 to be in an open conformation, fully activated by calcium.
Endostatin is not a glutaminyl substrate of transglutaminase-2
We performed enzymatic assays to determine if endostatin was a substrate of TG-2.
Endostatin was incubated with the enzyme in the presence of an acyl donor, i.e. the
biotinylated peptide TVQQEL. Analysis of the reaction products by SDS-PAGE and
immunoblotting showed that the biotinylated peptide was cross-linked to endostatin, and to a
lesser extent to the enzyme (Figure 5A). The amount of incorporated peptide increased as a
function of time. In absence of TG-2, or in presence of a Ca2+ ion chelator (20 mM EDTA),
the biotinylated peptide was not cross-linked with either endostatin or TG-2.
Immunodetection with a polyclonal anti-endostatin antibody showed that endostatin was not
cross-linked to itself or to TG-2 under those experimental conditions (Figure 5B). When
endostatin was reacted with the biotinylated peptide TVQQEL in the presence of TG-2 and
GTP, the amount of peptide incorporated into endostatin decreased when GTP concentration
increased (Figure 6A), whereas the amount of endostatin did not change in these conditions
(Figure 6B). The incorporation of the peptide was totally inhibited by 500 µM GTP as
shown in Figure 6 A. Since GTP is an inhibitor of the transamidating activity of TG-2, these
results confirm that the cross-linking of endostatin to TVQQEL is mediated by the
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transamidating activity of TG-2 and that endostatin behaves as an acyl acceptor in the
transamidation reaction.
When endostatin was incubated with TG-2 and cadaverin, an acyl acceptor, no crosslinking
reaction was detected, even when the reaction was performed with an increased amount of
enzyme (10 U/ml instead of 5 mU/ml) and for a longer period time (120 min versus 60 min,
Figure 7A and B). These results show that endostatin is an acyl acceptor, but not an acyl
donor in the transamidation reaction catalyzed by TG-2. Preliminary results showed that
endostatin did not inhibit the cross-linking activity of transglutaminase-2 in vitro
(Supplementary material Fig. S6), suggesting that endostatin does not bind to the
transamidating active site of TG-2.
Endostatin and transglutaminase-2 are co-localized in the extracellular matrix secreted by
endothelial cells and in vessel walls
To determine if the binding of endostatin with TG-2 occurs within the extracellular matrix
secreted by endothelial cells and/or at the cell surface, immunostaining experiments were
performed with anti-endostatin and anti-transglutaminase antibodies. Since hypoxia induces
COL18A1 gene in a HIF-1α dependent manner in endothelial cells [36], human umbilical
cord endothelial cells (HUVEC) were incubated in a hypoxic environment for six days to
enhance detection of endostatin (i.e. by immunofluorescence). Indeed an increased level of
endostatin was detected in the extracellular matrix synthesized by cultured endothelial cells
under hypoxia, that stimulates angiogenesis, compared to normoxia (Figure 8A and B). As
can be seen from Figure 8, transglutaminase-2 co-localized with endostatin/collagen XVIII
in the extracellular matrix secreted by HUVEC cultured under hypoxic conditions (Figure
8C–E). We have confirmed the co-localization of transglutaminase-2 and endostatin in
tissue by performing double immunostaining of foreskin sections with antibodies directed
against TG-2 and endostatin. TG-2 and endostatin were co-localized in vessel walls
(Supplementary material Fig. S7).
DISCUSSION
The interaction between endostatin and TG-2 was demonstrated by SPR and by solid-phase
assays with two different sources of transglutaminase (human recombinant TG-2 and guinea
pig TG-2 extracted from liver), and two different sources of recombinant human endostatin
(produced by HEK 293 EBNA cells or in yeast). These experiments revealed that endostatin
binds to transglutaminase with affinity in the nanomolar range and in a cation-dependent
manner, calcium ions being the most potent among those assayed.
TG-2 catalyzes post-translational modification of proteins by the formation of γ-glutamyl-ε-
lysine bonds between glutamine and lysine residues. Endostatin contains eight glutamine
residues that could potentially act as glutaminyl substrates (acyl donors) in the
transamidation reaction. However, endostatin is not a glutaminyl substrate of TG-2 in vitro,
but rather an acyl acceptor providing lysine residues in the transamidation reaction. This is
in agreement with the fact that none of the glutamine residues of endostatin is found within a
QXP sequence, a preferred sequence for glutamine-donor substrates where X represents a
variable amino acid [37] and with the fact that the N-terminus of endostatin contains a QP
(Q7P8) sequence reported to abolish transamidation [37]. The LGQS sequence found in the
N-propeptide of the α1 chain of procollagen III, a physiological substrate of TG-2 [38], is
present in endostatin (residues 158–161) but it is located on the side of endostatin that is not
involved in the binding to TG-2. Therefore the glutamine residue 160 does not appear to be
a glutaminyl substrate of TG-2.
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GTP inhibits the binding of endostatin to tranglutaminase-2, suggesting that endostatin
could bind to the GTP binding site on TG-2. However, the binding of endostatin to TG-2 is
calcium-dependent and calcium is known to activate TG-2 by switching on its
transamidating (i.e. cross-linking) activity [15]. Since the activation of TG-2 by Ca2+ can be
counteracted by the allosteric inhibitor GTP [35], the inhibition of endostatin binding by
GTP might alternatively suggest that endostatin binds to the transamidating active form of
the enzyme. Thus, we used TG-2 in an extended, active, conformation [39] to further
investigate the location of the endostatin binding site on TG-2. We have shown here that
R27 and/or R139 residues participate in the binding of endostatin to TG-2. These residues
both form part of a large basic patch on endostatin, comprising the heparin-binding site [19],
that is likely to interact with negatively charged amino acids on TG-2 surface. In addition to
our experimental data, we have used the Connolly molecular surface of TG-2 to have clues
on possible binding site(s) of endostatin on TG-2. There are three negatively charged areas
on the enzyme: one in the N-terminal β-sandwich domain, one close to transamidating
catalytic core, and a third one close to the GTP-binding site. We have shown that endostatin
does not interfere with TG-2 cross-linking activity in vitro and that GTP blocks the binding
of endostatin to TG-2. These results suggest that endostatin may bind to, or close to, the
GTP binding site but not to the transamidating active site of TG-2.
The requirement of calcium ions for endostatin binding to TG-2 suggests as discussed above
that endostatin binds to the open form of the enzyme. Extracellular TG-2 is predominantly
maintained in the catalytically inactive closed conformation under ordinary physiological
conditions, and is able to promote cell adhesion, spreading, migration, or differentiation
independently of its catalytic activity [15]. Extracellular TG-2 is transiently activated in
response to innate immune signals such as exposure to polyinosinic-polycytidylic acid, a
potent ligand of the toll-like receptor TLR-3 [40]. The stimulation of innate immune pattern
recognition receptors such as TLR3 triggers the release of extracellular TG-2 from cell
surface integrins and the concomitant enzyme activation [40]. It is thus possible that in the
course of angiogenesis up-regulated innate immune receptors trigger the activation of
extracellular TG-2 leading in turn to endostatin binding. This hypothesis is supported by the
fact that multiple human endothelial cell types express surface TLR3, which play a key role
in disrupting the haemostasis balance on endothelial cells [41], and by the suppression of
sequence- and target-independent angiogenesis by siRNA via TLR3 [42].
Endostatin might cooperate with TG-2 in several physio-pathological processes either
through direct interactions or through more complex mechanisms involving multimolecular
complexes. Direct interactions between endostatin and TG-2 might play a role in organizing
the extracellular matrix in skin basement membrane, endostatin being present in this location
[43], and TG-2 stabilizing basement membranes [44]. At the endothelial cell surface,
endostatin inhibits both the extracellular activation of proMMP-2 by inhibition of MT1-
MMP as well as the catalytic activity of MMP-2, thus blocking the invasiveness of tumor
cells [45]. MMP-2, functioning in concert with MT1-MMP, hydrolyzes cell-surface-
associated TG-2, and the cleavage eliminates both the adhesion and the enzymatic activity
of TG-2 [46]. It should be noted that endostatin and TG-2 bind to the catalytic domain of
MMP-2, and both proteins inhibit MMP-2 maturation [46,47].
Besides MMP-2, endostatin and TG-2 share heparan sulfate, VEGF-R2 and integrins as
binding partners at the cell surface, and both regulate endothelial cell adhesion
[3,6,10,11,48]. As reported here, two arginine residues implicated in the binding of
endostatin (R27 and/or R139) to TG-2 are also involved in the binding to α5β1 and αvβ3
integrins [4], and to heparin [19]. This suggests that endostatin is not able to bind
simultaneously to TG-2 and α5β1/αvβ3 integrins or to TG-2 and heparan sulfate. The co-
localization of endostatin/collagen XVIII and TG-2 in the extracellular matrix secreted by
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cultured endothelial cells indicates that this interaction may occur in a cellular context and
supports its physiological relevance. These proteins are co-localized in the extracellular
matrix synthesized under hypoxia that stimulates angiogenesis. This raises the possibility
that endostatin and TG-2 regulate endothelial cell behaviour and control angiogenesis in a
concerted fashion. However, their molecular interplay in the extracellular matrix secreted by
endothelial cells and/or at the surface of these cells remains to be deciphered.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Abbreviations
BSA Bovine serum albumin
ES endostatin
HBS Hepes-Buffered-Saline
GTP Guanosine 5'-triphosphate
HEK Human embryonic kidney
HIF Hypoxia-inducible factor
HUVEC Human umbilical vein endothelial cells
MMP-2 Matrix metalloproteinase-2
MT-MMP1 Membrane type matrix metalloproteinase-1
PBS Phosphate-buffered-saline
PNPP p-nitrophenyl phosphate
RU Resonance unit
SPR Surface plasmon resonance
TBS Tris-buffered-saline
TG-2 Transglutaminase-2
TLR3 Toll-like receptor-3
TMB 3,3',5,5'-Tetramethylbenzidine
VEGF Vascular endothelial growth factor
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Figure 1. TG-2 binds to endostatin and to the trimeric C-terminal NC1 domain of collagen XVIII
A) Overlay of sensorgrams resulting from the injection of human TG-2 (500 nM) over
immobilized wild-type NC1 (—, 154 pg) and wild-type endostatin (–––, 300 pg) (flow rate
500 µl/min). B) Solid-phase binding assay. Binding of human TG-2 (350 nM) to
immobilized wild type and mutant endostatin and NC1(XVIII) domain (0.5 µg/well).
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Figure 2. Soluble and immobilized endostatin bind to TG-2
Solid-phase binding assays. A) Binding of recombinant human endostatin (500 nM)
produced in mammalian (■) or yeast (□) expression systems to immobilized TG-2 (mean of
3 experiments ±SD). B) Binding of human (□, 350 nM) and guinea pig TG-2 (■, 350 nM) to
immobilized mammalian human endostatin. The values are expressed as mean ± SD (n=3).
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Figure 3. The binding of endostatin to TG-2 is cation-dependent
A) Solid-phase assays: effect of cations. Binding of human TG-2 (64 nM) to coated
endostatin produced in HEK 293 cells (0.1 µg/well) in the presence of cations (8 mM).
(mean of 3 experiments ±SD) B) Binding of human TG-2 (0, 1, 2, 4, 8, 16, 32, 64, 128, 256
nM to immobilized human endostatin (––– wild-type endostatin, — D104N mutant
endostatin; 0.1 µg/well) in the presence of 8 mM CaCl2. The values are expressed as mean ±
SD (n=3).
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Figure 4. GTP inhibits the binding of TG-2 to endostatin
A) Solid-phase binding assays: Effect of GTP (0–100 µM) on the binding of human TG-2
(64 nM) to endostatin (expressed in HEK cells; 0.1 µg/well) in presence of 8 mM CaCl2.
The values are expressed as mean ± SD (n=3); B) SPR binding assays: injection of guinea
pig TG-2 (130 nM) with (—) or without (–––) 1 mM GTP over immobilized human
endostatin.
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Figure 5. Endostatin is as an acyl acceptor in the transamidation reaction catalyzed by TG-2
Cross-linking experiments: Reaction between endostatin (476 nM) and the biotinylated
peptide TVQQEL-OH mediated by guinea pig TG-2 (5 mU/ml). The reaction was carried
out for 0, 2, 5, 10, 20, 30 and 60 min at room temperature. Results were analyzed by
immunoblotting using A) extravidin-peroxidase, and B) polyclonal antibody against
endostatin.
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Figure 6. GTP inhibits the cross-linking between endostatin and an acyl donor mediated by
guinea pig TG-2
Reaction between endostatin (476 nM) and the biotinylated peptide TVQQEL-OH mediated
by guinea pig TG-2 (5 mU/ml). Reactions were carried out for 60 min at room temperature
in absence of GTP or in presence of increased GTP concentrations (10 – 500 µM). Results
were analyzed by immunoblotting using A) extravidin-peroxidase, and B) polyclonal
antibody against endostatin.
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Figure 7. Endostatin is not a glutaminyl substrate of TG-2
Cross-linking experiments: Reaction between endostatin (ES, 476 nM) and biotin-X-
cadaverin (Cad) in presence of human or guinea pig TG-2 (10 mU/ml). Analysis of the
reaction products by immunoblotting using A) extravidin-peroxidase, and B) anti endostatin
antibody.
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Figure 8. Endostatin and TG-2 are co-localized in the extracellular matrix synthesized by
HUVECs under hypoxia
Confocal microscopy: immunostaining of endostatin/ collagen XVIII (A–C), and TG-2 (D),
merge (E) in the extracellular matrix secreted by cultured HUVECs. Cells were grown to
confluence in normoxia (A) or hypoxia (B–E). Nuclei (blue) were stained using TO-PRO-3.
Bar = 30 µm.
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Table 1
Kinetic and equilibrium dissociation constants of the binding of transglutaminase-2 to
endostatin
Rate and affinity constants of the binding of soluble transglutaminase-2 to immobilized endostatin calculated
from SPR binding assays using the Biacore T100 evaluation software 2.0.1.
Endostatin
(Immobilized on
the chip)
HEK 293 EBNA
cells
P. pastoris
Guinea pig TG-2
Injected in soluble
form
+ 2 mM CaCl2 + 2 mM CaCl2
ka (M−1s−1) 1.12×105 M−1 s−1 6.10 ×104 M−1 s−1
kd (s−1) 7.65×10−4 s−1 3.41×10−4 s−1
KD (M) 6.8 nM 5.59 nM
Chi2 4.1 8.81
U-value 1 1
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